A 1972 BMW 3.0 CSL, one of the most iconic homologation specials in the automaker’s history, is now up for auction via RM Sotheby’s. This Italian-market, second-series example has been meticulously ...

You have reached your maximum number of saved items. Remove items from your saved list to add more. CSL investors had already torched tens of billions of dollars of wealth on the biomedical giant ...

Amid the drama at the biotech, a new figure has stepped up right as the company needs a new long-term chief executive and chairman. Brian McNamee is CSL’s immovable object and unstoppable force. But ...

At the time of writing, the shares are down another 0.22% to $98.33 a piece. Although at one point earlier this morning, the shares were up 2.3% to $100.80 each. It's more bad news for investors after ...

Investors on Monday stripped billions from CSL’s market capitalisation, triggered by news of the impairment against its unpopular Vifor renal therapy acquisition, and the prospect of revenue and ...

Few stocks have earned a place in the Australian investor psyche quite like CSL (CSL). Listed in 1994 at a split-adjusted price of less than $1, it spent the better part of three decades compounding ...

Biotechnology business CSL, which specialises in bloods, vaccines and plasma products, flagged a US$5 billion (AU$6.9 billion) write-down of its assets. The Melbourne-headquartered company also ...

In a 90-day review, CSL told the market it would take another $US5bn ($A6.9bn) non-cash impairment. The first $1.5bn of this was recognised during the first-half ...

CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the Australian company’s financial distress since its ill-fated 2022 ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

CSL has lost the trust of major investors after slashing earnings forecasts reaffirmed three months ago and announcing one of the biggest write-downs in Australian corporate history as the healthcare ...

Shares in health giant CSL tanked today, with the stock closing 16 per cent lower, at $100.75. At earlier points in the session, the stock was down more than 20 per cent, sinking below $100 to decade ...